CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: October 17, 2014
Result type: Reports
Project Number: SR0401-000
Product Line: Reimbursement Review

Generic Name: Aflibercept

Brand Name: Eylea

Manufacturer: Bayer Inc.

Therapeutic Area: Macular edema, central retinal vein occlusion

Indications: Macular edema secondary to central retinal vein occlusion

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: May 7, 2015

Recommendation Type: List with clinical criteria and/or conditions